Navigation Links
Iomai Receives HHS Approval to Begin Phase 2 Trial of H5N1 Influenza Adjuvant Patch
Date:4/15/2008

- Dose-Ranging Trial to Further Assess Feasibility of Dose-sparing and

Single-Dose Vaccination Against H5N1 Flu -

GAITHERSBURG, Md., April 15 /PRNewswire-FirstCall/ -- Iomai Corporation (Nasdaq: IOMI) today announced that it has received approval from the Department of Health and Human Services (HHS) to expand its program to develop an immunostimulant adjuvant patch for use with an injected H5N1 influenza vaccine. This decision was based upon positive clinical data generated in a 500-subject, Phase 1/2 study recently completed by Iomai.

Guided by data from this study, Iomai will begin a Phase 2 dose-ranging study designed to identify the optimum dose of antigen and adjuvant that can be used in a one-dose or two-dose regimen to enhance the immune response to a H5N1 influenza vaccine. As the majority of current approaches to pandemic influenza vaccines require two doses, given 3 or 4 weeks apart, a single-dose strategy would significantly simplify the logistics of a mass vaccination program.

Last month, Iomai announced the results of the first clinical trial of the patch when used with an injectable H5N1 influenza vaccine. That trial found that a single 45-microgram dose of an H5N1 influenza vaccine, coupled with a single 50-microgram Iomai adjuvant patch, was sufficient to provide an immune response considered protective in 73 percent of those tested, a statistically significant improvement over those who received the H5N1 influenza vaccine alone. A second dose of both vaccine and patch further enhanced immunogenicity; 100 percent of subjects who received two 45-microgram doses of vaccine and two Iomai patches had a measurable immune response, and 94 percent of these subjects had immune responses cons
'/>"/>

SOURCE Iomai Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
2. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
3. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
4. Iomai CEO to Speak at Acumen BioFin Rodman & Renshaw Annual Healthcare Conference on Monday, Nov. 5
5. Iomai and Merck & Co., Inc. Evaluate Use of Iomai Immunostimulant Patch
6. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
7. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
9. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
10. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
11. CryoCor Receives FDA Approval for Right Atrial Flutter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... Ranbaxy Laboratories Limited (hereafter, Ranbaxy), a ... Sankyo), announced on May 22 the actions that ... past conduct under prior management ... continues to support Ranbaxy in its efforts to ... which led to the investigations by the U.S. ...
(Date:5/22/2013)... Israel , May 22, 2013  Rosetta ... developer and provider of microRNA-based molecular diagnostics, announces that ... Chief Executive Officer of Rosetta Genomics, will deliver a ... place from June 3-6, 2013 in New York City.  ... 4 th at 2:00 p.m. Eastern time. ...
(Date:5/22/2013)... 22, 2013  BD (Becton, Dickinson and Company) (NYSE: ... company, announced today the publication of its 2012 ... and it continues to focus on the Company,s shared ... the principles of shared value — creating value for ... societies — are fundamental to our strategy," said ...
Breaking Medicine Technology:Rosetta Genomics to Present at the Jefferies 2013 Healthcare Conference 2Rosetta Genomics to Present at the Jefferies 2013 Healthcare Conference 3BD Issues 2012 Sustainability Report 2BD Issues 2012 Sustainability Report 3
... , , SAN DIEGO, Sept. ... a leader in adult stem cell research and manufacturing, announced today ... California,s Food & Drug Branch to manufacture stem cells for human ... with California law and the applicable provisions of the Code of ...
... Conn., Aug 31 The results of the initial clinical trial ... for varicose veins, will be delivered on Wednesday, September 2, at ... Monaco. The device combines mechanical and chemical modalities to accomplish vein ... is Steve Elias MD FACS FACPh, Associate Professor of Surgery at ...
Cached Medicine Technology:Stemedica Achieves Major Milestone - Company Receives License to Manufacture Clinical Grade Stem Cells 2ClariVein(TM) Catheter for Varicose Veins: Clinical Trial Results to be Presented 2
(Date:5/22/2013)... HealthDay Reporter , , WEDNESDAY, May 22 (HealthDay News) -- ... of suffering, but new research indicates the combination of ... -- a smaller brain. , , Already aware that ... scientists wanted to determine if having both conditions together ... about 2 percent -- isn,t alarming, study authors said, ...
(Date:5/22/2013)... Phelps Memorial Hospital Center in ... Nodule Center for individuals who would like to be ... cancer is the deadliest form of cancer for both men ... die from lung cancer than from breast, colon and prostate ... increases survival rates. It is well established that routine ...
(Date:5/22/2013)... Registered Dietitian and Founder of Tatalou Science Nathalie ... a recipe for making energy bars at home. , The ... takes a recipe modified from one recently featured on ... it gets more and more difficult to understand what ingredients ... of the nutrition label continues to grow and consumers are ...
(Date:5/22/2013)... HR Strategies recently participated in the Gwinnett ... Fairgrounds, on Friday May 10, 2013. For never having ... raising over $6,300 for cancer research. , HR ... the first $3,000 for Bronze Level Sponsorship. HR Strategies ... to match the company’s contribution of $3,000; and after ...
(Date:5/22/2013)... Go Classy the Original Nudist Travel ... of their newest website http://www.Desire-Mexico.com . The seductively ... Desire Resorts have become the premier Nudist and Lifestyle ... total liberation while allowing you to enjoy a deluxe ... Classy Tours / Caribbean-Hideaways. He goes on to say ...
Breaking Medicine News(10 mins):Health News:Having Both Migraines, Depression May Mean Smaller Brain 2Health News:Having Both Migraines, Depression May Mean Smaller Brain 3Health News:Phelps Memorial Hospital Center Establishes The Westchester Lung Nodule Center To Diagnose And Administer Lung Cancer Care 2Health News:Phelps Memorial Hospital Center Establishes The Westchester Lung Nodule Center To Diagnose And Administer Lung Cancer Care 3Health News:How To "Make Your Own Healthy Energy Bars" 2Health News:HR Strategies Raises Over $6,300 for Cancer Research via Relay For Life 2Health News:Go Classy Tours Announces the Launch of Their Newest Website for Desire Resorts Located in Mexico Clothing Optional/Aunaturel Resorts a Lovers Paradise 2
... could soon be offered better treatment thanks to a new ... The University of Nottingham. A purpose-built MRI research ... diseases. The unit is based at the Queens Medical Centre ... of patients using a new, specifically-adapted MRI scanner. ...
... may yield insight into therapies for people, researchers say ... with cancer could provide crucial insight into the human ... and screening for tumors, researchers from the U.S. National ... findings appear in the Oct. 13 online journal ...
... REDONDO BEACH, Calif., Oct. 13 Function Drinks announced ... signed onto the faculty of the Hospital for Special ... as a clinical instructor and attending in spinal surgery. ... research and development for Function Drinks, a line of ...
... SPRING, Texas, Oct. 13 Go Healthy, Inc. (Pink Sheets: ... agreement with Hydro Enterprises, Inc., and Planet Green Solutions, Inc., ... that produces water from any source at a 9.5 pH ... , The ability to place the machines in bottling plants ...
... Oct. 13 Interleukin Genetics, Inc. (NYSE Amex: ILI ) ... of obesity and osteoporosis at medical meetings later this month. The ... and Nutrition Conference & Expo in Denver, Colo. , ... World Diabetes Congress - Montreal, Canada . , Date: ...
... Berger, Managing Member and Founder of Omni Management ... new office in Midtown Manhattan, located at 1120 Avenue of ... strategic geographic expansion," said Berger, "because it just makes good ... , Omni Management Group, LLC ...
Cached Medicine News:Health News:A new scan for lung diseases 2Health News:Dogs Helping to Advance Cancer Research 2Health News:Function Drinks' President & Co-Founder, Dr. Alex Hughes, Joins the Faculty of Cornell's Hospital for Special Surgery 2Health News:Go Healthy Secures Nationwide Distributorship Rights to Patented Drinking Water 2Health News:Go Healthy Secures Nationwide Distributorship Rights to Patented Drinking Water 3Health News:Interleukin Genetics to Present Research Findings at Upcoming Medical Meetings 2Health News:Interleukin Genetics to Present Research Findings at Upcoming Medical Meetings 3Health News:Omni Management Group Announces Opening of New York Office 2
The longer working distances achieved by the use of Galilean optics make this the perfect magnifier to enable the patient to read and write....
This full segment bifocal can be screwed into a hole in a corrective or plano lens, or mounted directly on top of a prescription lens....
An intermediate set providing a greater range of telescopes than the starter set....
This set is designed to introduce the low vision practitioner to the Keeler telescopic system....
Medicine Products: